|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
178,600,000 |
Market
Cap: |
242.90(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.8901 - $1.85 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 7.4 |
Insider 3/6 Months : 8 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Precigen is a clinical-stage biopharmaceutical company improving gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. In addition, Co. has completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
96,686 |
1,592,031 |
13,134,243 |
Total Buy Value |
$0 |
$136,327 |
$2,615,293 |
$22,822,494 |
Total People Bought |
0 |
1 |
4 |
8 |
Total Buy Transactions |
0 |
1 |
6 |
12 |
Total Shares Sold |
0 |
96,686 |
455,706 |
505,706 |
Total Sell Value |
$0 |
$136,327 |
$650,097 |
$765,097 |
Total People Sold |
0 |
1 |
6 |
6 |
Total Sell Transactions |
0 |
1 |
21 |
22 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sabzevari Helen |
President and CEO |
|
2020-05-15 |
4 |
AS |
$2.37 |
$515,800 |
D/D |
(217,527) |
389,365 |
|
26% |
|
Sabzevari Helen |
President and CEO |
|
2020-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
500,000 |
606,892 |
|
- |
|
Sabzevari Helen |
President and CEO |
|
2020-04-01 |
4 |
AS |
$3.01 |
$16,415 |
D/D |
(5,450) |
106,892 |
|
34% |
|
Sterling Rick L. |
Chief Financial Officer |
|
2020-04-01 |
4 |
AS |
$3.02 |
$14,859 |
D/D |
(4,927) |
152,445 |
|
34% |
|
Lehr Donald P. |
Chief Legal Officer |
|
2020-04-01 |
4 |
AS |
$3.01 |
$16,415 |
D/D |
(5,450) |
102,881 |
|
34% |
|
Perez Jeffrey Thomas |
SVP, IP Affairs |
|
2020-04-01 |
4 |
AS |
$3.01 |
$14,830 |
D/D |
(4,927) |
90,361 |
|
34% |
|
Sabzevari Helen |
President and CEO |
|
2020-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,340 |
112,342 |
|
- |
|
Sterling Rick L. |
Chief Financial Officer |
|
2020-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,340 |
157,372 |
|
- |
|
Kirk Randal J |
Executive Chairman |
|
2020-03-31 |
4 |
A |
$2.61 |
$199,999 |
I/I |
76,628 |
10,588,601 |
|
- |
|
Lehr Donald P. |
Chief Legal Officer |
|
2020-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,340 |
108,331 |
|
- |
|
Perez Jeffrey Thomas |
SVP, IP Affairs |
|
2020-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,340 |
95,288 |
|
- |
|
Kirk Randal J |
Executive Chairman |
|
2020-03-20 |
4 |
B |
$2.72 |
$1,143,314 |
I/I |
420,336 |
10,511,973 |
2.64 |
72% |
|
Kirk Randal J |
Executive Chairman |
|
2020-03-19 |
4 |
B |
$1.87 |
$1,098,311 |
I/I |
579,664 |
10,091,637 |
2.64 |
71% |
|
Hassan Fred |
Director |
|
2020-03-13 |
4 |
A |
$2.01 |
$56,499 |
D/D |
28,109 |
85,170 |
|
- |
|
Shapiro Robert B |
Director |
|
2020-03-13 |
4 |
A |
$2.01 |
$62,999 |
D/D |
31,343 |
123,551 |
|
- |
|
Mitchell Dean J |
Director |
|
2020-03-13 |
4 |
A |
$2.01 |
$56,499 |
D/D |
28,109 |
102,473 |
|
- |
|
Gupta Vinita D |
Director |
|
2020-03-13 |
4 |
A |
$2.01 |
$56,499 |
D/D |
28,109 |
78,303 |
|
- |
|
Kindler Jeffrey B |
Director |
|
2020-03-13 |
4 |
A |
$2.01 |
$68,999 |
D/D |
34,328 |
143,071 |
|
- |
|
Frank Steven |
Director |
|
2020-03-13 |
4 |
A |
$2.01 |
$49,999 |
D/D |
24,875 |
262,595 |
|
- |
|
Alvarez Cesar L |
Director |
|
2020-03-13 |
4 |
A |
$2.01 |
$62,499 |
D/D |
31,094 |
181,165 |
|
- |
|
Turley James S |
Director |
|
2020-03-13 |
4 |
A |
$2.01 |
$62,499 |
D/D |
31,094 |
89,609 |
|
- |
|
Mitchell Dean J |
Director |
|
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
74,364 |
|
- |
|
Hassan Fred |
Director |
|
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
57,061 |
|
- |
|
Frank Steven |
Director |
|
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
237,720 |
|
- |
|
Kindler Jeffrey B |
Director |
|
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
108,743 |
|
- |
|
617 Records found
|
|
Page 13 of 25 |
|
|